Drug intelligence / Profile preview

clonazepam + gabapentin + methylprednisolone

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

This is a combination of three pharmaceutical drugs—clonazepam, gabapentin, and methylprednisolone. - **Clonazepam** is a benzodiazepine used primarily for seizure disorders (such as Lennox-Gastaut syndrome, absence seizures, myoclonic seizures) and panic disorder. It acts by enhancing the effect of gamma-aminobutyric acid (GABA) at GABA(a) receptors in the central nervous system, leading to increased neuronal inhibition and resulting in anticonvulsant, anxiolytic, sedative, and muscle relaxant effects[4]. - **Gabapentin** is an anticonvulsant/antiepileptic drug also used for neuropathic pain. Its mechanism involves binding to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, reducing excitatory neurotransmitter release[6]. Gabapentin does not significantly induce or inhibit hepatic enzymes and has minimal pharmacokinetic interactions with other antiepileptics[7]. - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It works by modulating gene expression after binding to glucocorticoid receptors; this leads to decreased production of pro-inflammatory cytokines and mediators[2]. There are no fixed-dose combination products containing all three agents; their co-administration would be off-label or based on specific clinical needs.

02

Targets

CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on clonazepam + gabapentin + methylprednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clonazepam + gabapentin + methylprednisolone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call